Impax Laboratories Inc (IPXL)-Financial and Strategic SWOT Analysis Review
- Table Of Content
- Licence Rights
- Section Purchase
- Products and Companies
Impax Laboratories Inc (IPXL)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Business description-A detailed description of the company's operations and business divisions.
Corporate strategy-Analyst's summarization of the company's business strategy.
SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.
Company history-Progression of key events associated with the company.
Major products and services-A list of major products, services and brands of the company.
Key competitors-A list of key competitors to the company.
Key employees-A list of the key executives of the company.
Executive biographies-A brief summary of the executives' employment history.
Key operational heads-A list of personnel heading key departments/functions.
Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.
Key manufacturing facilities-A list of key manufacturing facilities of the company.
Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Impax Laboratories Inc (Impax) is a pharmaceutical company develops, manufacture and market generic and branded pharmaceuticals by applying its formulation expertise and drug delivery technology. The company operates develops and markets proprietary branded products for CNS disorders and manufactures and markets generic pharmaceutical products representing dosage variations of several pharmaceutical compounds. The company develops marketing partnerships to leverage its technology platform and to offer alternative dosage form technologies, such as nasal sprays, injectable, patches and others. It distributes its generic pharmaceutical products through wholesalers, large retail drug chains, unrelated third-party pharmaceutical entities and others. The company has manufacturing facilities in Hayward, California; Middlesex, New Jersey; and Taiwan. Impax is headquartered in Hayward, California, the US.
Impax Laboratories Inc Key Recent Developments
Mar 27,2017: Impax Board of Directors Appoints Paul M. Bisaro President and CEO
Mar 01,2017: Impax Reports Fourth Quarter and Full Year 2016 Financial Results
Dec 20,2016: Impax Laboratories Announces Leadership Transition
Nov 28,2016: Impax Laboratories appoints new board member
Nov 09,2016: Impax Reports Third Quarter 2016 Financial Results
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table Of Content
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Section 1-About the Company 5
Impax Laboratories Inc-Key Facts 5
Impax Laboratories Inc-Key Employees 6
Impax Laboratories Inc-Key Employee Biographies 7
Impax Laboratories Inc-Major Products and Services 8
Impax Laboratories Inc-History 9
Impax Laboratories Inc-Company Statement 14
Impax Laboratories Inc-Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Section 2-Company Analysis 18
Impax Laboratories Inc-Business Description 18
Impax Laboratories Inc-Corporate Strategy 19
Impax Laboratories Inc-SWOT Analysis 20
SWOT Analysis-Overview 20
Impax Laboratories Inc-Strengths 20
Impax Laboratories Inc-Weaknesses 21
Impax Laboratories Inc-Opportunities 22
Impax Laboratories Inc-Threats 23
Impax Laboratories Inc-Key Competitors 24
Section 3-Company Financial Ratios 25
Financial Ratios-Capital Market Ratios 25
Financial Ratios-Annual Ratios 26
Performance Chart 29
Financial Performance 29
Financial Ratios-Interim Ratios 30
Financial Ratios-Ratio Charts 31
Section 4-Company's Lifesciences Financial Deals and Alliances 32
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 32
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 33
Impax Laboratories Inc, Recent Deals Summary 34
Section 5-Company's Recent Developments 35
Mar 27, 2017: Impax Board of Directors Appoints Paul M. Bisaro President and CEO 35
Mar 01, 2017: Impax Reports Fourth Quarter and Full Year 2016 Financial Results 36
Dec 20, 2016: Impax Laboratories Announces Leadership Transition 39
Nov 28, 2016: Impax Laboratories appoints new board member 40
Nov 09, 2016: Impax Reports Third Quarter 2016 Financial Results 41
Aug 22, 2016: Richard A. Bierly Appointed to Impax Laboratories Board of Directors 43
Aug 09, 2016: Impax Reports Second Quarter 2016 Financial Results 44
Jul 21, 2016: Impax Names Douglas S. Boothe President of Generics Division 46
May 10, 2016: Impax Reports First Quarter 2016 Financial Results 47
Apr 14, 2016: Impax Announces the Retirement of Nigel Ten Fleming, Ph.D. and Michael Markbreiter from its Board of Directors 48
Section 6-Appendix 49
Ratio Definitions 49
About GlobalData 53
Contact Us 53
List Of Figure
List of Figures
Impax Laboratories Inc, Performance Chart (2012-2016) 30
Impax Laboratories Inc, Ratio Charts 32
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 33
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 34
List Of Table
List of Tables
Impax Laboratories Inc, Key Facts 6
Impax Laboratories Inc, Key Employees 7
Impax Laboratories Inc, Key Employee Biographies 8
Impax Laboratories Inc, Major Products and Services 9
Impax Laboratories Inc, History 10
Impax Laboratories Inc, Other Locations 17
Impax Laboratories Inc, Subsidiaries 17
Impax Laboratories Inc, Key Competitors 25
Impax Laboratories Inc, Ratios based on current share price 26
Impax Laboratories Inc, Annual Ratios 27
Impax Laboratories Inc, Annual Ratios (Cont...1) 28
Impax Laboratories Inc, Annual Ratios (Cont...2) 29
Impax Laboratories Inc, Interim Ratios 31
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 33
Impax Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 34
Impax Laboratories Inc, Recent Deals Summary 35
Currency Codes 50
Capital Market Ratios 50
Equity Ratios 51
Profitability Ratios 51
Cost Ratios 52
Liquidity Ratios 52
Leverage Ratios 53
Efficiency Ratios 53
Single User License:
Report can be used by individual purchaser only
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Products and Companies
Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Par Pharmaceutical Holdings Inc, Mylan NV, Mapi Pharma Ltd, Lupin Pharmaceuticals Inc, Lannett Company Inc, Avanir Pharmaceuticals Inc, Allergan Plc